Produced by AVE, it has a high degree of automation, and the front end is equipped with automatic sample delivery device.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Eyonis Inc., a Median Technologies company focused on applying artificial intelligence to the early detection and diagnosis of cancer, today announced that Median Technologies has entered into a strategic commercial agreement with Olea Medical, a Canon Medical Systems company, that will expand U.S. access to eyonis® LCS Lung Cancer Screening. The broader agreement also covers Europe and other markets that may be mutually agreed upon over time.

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker.

The Board of Directors of Diasorin S.p.A. (FTSE MIB: DIA) meeting today, examined and approved the Group’s Consolidated Financial Statements at June 30, 2026.

Siemens Healthineers AG today announces its results for the third quarter of fiscal year 2026 ended June 30, 2026.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2026.

Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2026.

Intelligenome and Cornell University entered into a research and development subaward agreement to support the development of a rapid, low-cost, and portable diagnostic solution for tuberculosis (TB), according to the company. The project is part of a National Institutes of Health (NIH) funded program focused on improving access to technologies for human healthcare.

Alveo Technologies, Inc. (Alveo), a leader in portable molecular sensing solutions, today announced a strategic partnership with The University of Texas Medical Branch (UTMB) to develop point-of-care diagnostics for viral hemorrhagic fevers across West Africa. The point-of-care diagnostic will provide real-time pathogen detection at clinical sites in Nigeria and Sierra Leone, supporting UTMB's Lassa fever research program—a major international initiative.

bioMérieux, a world leader in the field of in vitro diagnostics, today announces the submission of the BIOFIRE® FILMARRAY® Gastrointestinal 1.1 (GI1.1) Panel and the BIOFIRE® FILMARRAY® Gastrointestinal 1.1 (GI1.1) Panel Mid to the U.S. Food and Drug Administration (FDA) for 510(k) review. These PCR* molecular panels test 22 and 11, respectively, of the most common bacteria, viruses, and parasites associated with gastroenteritis, all from one sample, with results available in approximately one hour.

Produced by DIRUI, it can meet the needs of intelligent, automated, and high-throughput urine dry chemical test in hospitals.